Biogen amends 8-K to note Apellis acquisition not significant, no financial statements required

BIOGEN INC.

Acquisition of Apellis closed May 14, 2026; deemed not significant under Regulation S-X after further analysis.
Items 9.01(a) and (b) financial statements and pro forma information not required; prior obligation withdrawn.
All other disclosures from the Original Report regarding the merger remain unchanged.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.